Author

Nam Seok Baek

Observed institution: National Cancer Center

ORCID: 0000-0003-3611-300X

Observed ORCID: 0000-0003-3611-300X

OpenAlex ID: A5000549975

Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety

2023 · Myongjae Lee, In-Gyu Je, et al. · Molecular Cancer Therapeutics · 15

A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.

2021 · Seock-Ah Im, SeungHwan Lee, et al. · Journal of Clinical Oncology · 11

Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor

2018 · Myongjae Lee, Joon-Tae Park, et al. · Molecular Cancer Therapeutics · 4

First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors.

2021 · Yong Man Kim, Kyun-Seop Bae, et al. · Journal of Clinical Oncology · 3

Abstract 4842: A comparative preclinical study of PARP inhibitors demonstrates superb properties for IDX-1197

2018 · Myongjae Lee, Joon-Tae Park, et al. · Cancer Research · 3

Quantification of venadaparib, a novel PARP inhibitor, in the rat and dog plasma using liquid chromatography/tandem mass spectrometry

2023 · Myongjae Lee, Eunhye Jang, et al. · Journal of Analytical Science & Technology · 1

Supplementary Data from Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety

2025 · Myongjae Lee, In-Gyu Je, et al.

Supplementary Data from Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety

2023 · Myongjae Lee, In-Gyu Je, et al.

Data from Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety

2023 · Myongjae Lee, In-Gyu Je, et al.

Works count: 9

Citation count: 37

H-index: 3

I10-index: 2